AU2010247464B2 - Humanized AXL antibodies - Google Patents

Humanized AXL antibodies Download PDF

Info

Publication number
AU2010247464B2
AU2010247464B2 AU2010247464A AU2010247464A AU2010247464B2 AU 2010247464 B2 AU2010247464 B2 AU 2010247464B2 AU 2010247464 A AU2010247464 A AU 2010247464A AU 2010247464 A AU2010247464 A AU 2010247464A AU 2010247464 B2 AU2010247464 B2 AU 2010247464B2
Authority
AU
Australia
Prior art keywords
seq
serine
threonine
axl
antibody
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2010247464A
Other languages
English (en)
Other versions
AU2010247464A1 (en
Inventor
Jens Ruhe
Tomoko Takayama
Takeshi Takizawa
Peter Wirtz
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Daiichi Sankyo Europe GmbH
Original Assignee
U3 Pharma GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from EP09006355A external-priority patent/EP2270053A1/en
Application filed by U3 Pharma GmbH filed Critical U3 Pharma GmbH
Publication of AU2010247464A1 publication Critical patent/AU2010247464A1/en
Application granted granted Critical
Publication of AU2010247464B2 publication Critical patent/AU2010247464B2/en
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/573—Immunoassay; Biospecific binding assay; Materials therefor for enzymes or isoenzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Physics & Mathematics (AREA)
  • Endocrinology (AREA)
  • Food Science & Technology (AREA)
  • Biotechnology (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Cell Biology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
AU2010247464A 2009-05-11 2010-05-11 Humanized AXL antibodies Ceased AU2010247464B2 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP09006355.3 2009-05-11
EP09006355A EP2270053A1 (en) 2009-05-11 2009-05-11 Humanized AXL antibodies
EP09006474 2009-05-13
EP09006474.2 2009-05-13
PCT/EP2010/056487 WO2010130751A1 (en) 2009-05-11 2010-05-11 Humanized axl antibodies

Publications (2)

Publication Number Publication Date
AU2010247464A1 AU2010247464A1 (en) 2011-11-10
AU2010247464B2 true AU2010247464B2 (en) 2014-09-11

Family

ID=42272537

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2010247464A Ceased AU2010247464B2 (en) 2009-05-11 2010-05-11 Humanized AXL antibodies

Country Status (15)

Country Link
US (2) US8841424B2 (enExample)
EP (1) EP2430050A1 (enExample)
JP (2) JP5909442B2 (enExample)
KR (1) KR20120035145A (enExample)
CN (1) CN102421802B (enExample)
AR (1) AR076564A1 (enExample)
AU (1) AU2010247464B2 (enExample)
BR (1) BRPI1013428A2 (enExample)
CA (1) CA2759836A1 (enExample)
IL (1) IL216147A (enExample)
MX (1) MX2011011825A (enExample)
RU (2) RU2571224C2 (enExample)
TW (2) TWI526223B (enExample)
WO (1) WO2010130751A1 (enExample)
ZA (1) ZA201107529B (enExample)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5909442B2 (ja) * 2009-05-11 2016-04-26 ユー３・ファーマ・ゲーエムベーハー ヒト化ａｘｌ抗体
EP2483289B2 (en) 2009-10-02 2025-03-26 Biogen MA Inc. Methods of preventing and removing trisulfide bonds
US9562252B2 (en) 2011-05-13 2017-02-07 Biogen Ma Inc. Methods of preventing and removing trisulfide bonds
US9409988B2 (en) * 2011-06-22 2016-08-09 Inserm (Institut National De La Sante Et De La Recherche Medicale) Anti-Axl antibodies and uses thereof
JP6033293B2 (ja) * 2011-06-22 2016-11-30 インサーム（インスティテュ ナシオナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシェ メディカル）Ｉｎｓｅｒｍ（Ｉｎｓｔｉｔｕｔ Ｎａｔｉｏｎａｌ Ｄｅｌａ Ｓａｎｔｅ Ｅｔ Ｄｅ Ｌａ Ｒｅｃｈｅｒｃｈｅ Ｍｅｄｉｃａｌｅ） 抗Ａｘｌ抗体及びその使用
EP2589609A1 (en) * 2011-11-03 2013-05-08 Pierre Fabre Medicament Antigen binding protein and its use as addressing product for the treatment of cancer
US9879061B2 (en) 2011-12-15 2018-01-30 The Board Of Trustees Of The Leland Stanford Junior University Inhibition of AXL/GAS6 signaling in the treatment of liver fibrosis
CA2890265C (en) * 2012-11-05 2023-01-17 Pierre Fabre Medicament Antigen binding proteins and their use as addressing product for the treatment of cancer
PT3326622T (pt) 2012-12-14 2021-04-07 Univ Leland Stanford Junior Péptidos axl modificados e sua utilização na inibição da sinalização de axl em terapêutica anti-metastática
EP3229836B1 (en) * 2014-12-09 2019-11-13 Institut National de la Sante et de la Recherche Medicale (INSERM) Human monoclonal antibodies against axl
EP3233119A2 (en) 2014-12-18 2017-10-25 Bergen Teknologioverforing AS Anti-axl antagonistic antibodies
GB201506411D0 (en) 2015-04-15 2015-05-27 Bergenbio As Humanized anti-axl antibodies
US10787517B2 (en) 2015-05-18 2020-09-29 Agensys, Inc. Antibodies that bind to AXL proteins
JP6857138B2 (ja) * 2015-05-18 2021-04-14 アジェンシス，インコーポレイテッド Ａｘｌタンパク質に結合する抗体
GB201509338D0 (en) 2015-05-29 2015-07-15 Bergenbio As Combination therapy
CA2991805A1 (en) 2015-07-10 2017-01-19 Genmab A/S Axl-specific antibody-drug conjugates for cancer treatment
EP4349997A3 (en) 2015-09-24 2024-07-10 Daiichi Sankyo Company, Limited Anti-garp antibody
AU2017248644B2 (en) * 2016-04-15 2019-10-31 Bioatla, Llc Anti-Axl antibodies, antibody fragments and their immunoconjugates and uses thereof
GB201610902D0 (en) 2016-06-22 2016-08-03 Bergen Teknologioverforing As And Bergenbio As Anti-Axl Antagonistic Antibodies
CN110536703B (zh) 2017-04-20 2024-07-12 Adc治疗有限公司 使用抗axl抗体-药物缀合物的组合疗法
CN110540592B (zh) * 2018-05-29 2022-08-09 杭州尚健生物技术有限公司 结合axl蛋白的抗体及其应用
CN109160941B (zh) * 2018-09-29 2020-09-04 未名生物医药有限公司 蛋白序列17e11及其用途
RU2678569C1 (ru) * 2018-10-31 2019-01-30 Гордейчук Владимир Евгеньевич Способ подавления метастазирования опухолей
GB201912059D0 (en) 2019-08-22 2019-10-09 Bergenbio As Combaination therapy of a patient subgroup
CN110982791A (zh) * 2019-12-26 2020-04-10 百泰生物药业有限公司 一种分泌axl抗体的杂交瘤细胞的制备筛选方法
EP4087657A1 (en) 2020-01-08 2022-11-16 Synthis Therapeutics, Inc. Alk5 inhibitor conjugates and uses thereof
BR112022015977A2 (pt) * 2020-02-28 2022-10-11 Symphogen As Anticorpos anti-axl e composições
GB202004189D0 (en) 2020-03-23 2020-05-06 Bergenbio As Combination therapy
IL297132A (en) 2020-04-08 2022-12-01 Bergenbio Asa axl inhibitors for antiviral therapy
GB202006072D0 (en) 2020-04-24 2020-06-10 Bergenbio Asa Method of selecting patients for treatment with cmbination therapy
MX2023008744A (es) 2021-01-29 2023-10-02 Illimis Therapeutics Inc Molecula de fusion que tiene actividad no inflamatoria inductora de la fagocitosis.
GB202104037D0 (en) 2021-03-23 2021-05-05 Bergenbio Asa Combination therapy
CN115927243A (zh) * 2022-09-13 2023-04-07 中山大学 一种akt1蛋白的抑制性磷酸化位点及其应用
CN116715774B (zh) * 2023-05-12 2023-11-24 武汉爱博泰克生物科技有限公司 针对人axl的兔单克隆抗体及其制备方法和应用

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5468634A (en) * 1991-06-24 1995-11-21 The University Of North Carolina At Chapel Hill Axl oncogene
WO1997034636A1 (en) * 1996-03-20 1997-09-25 Immunomedics, Inc. Humanization of an anti-carcinoembryonic antigen anti-idiotype antibody and use as a tumor vaccine and for targeting applications
EP1382969A1 (en) * 2002-07-17 2004-01-21 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Diagnosis and prevention of cancer cell invasion
WO2009062690A1 (en) * 2007-11-12 2009-05-22 U3 Pharma Gmbh Axl antibodies

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4931385A (en) * 1985-06-24 1990-06-05 Hygeia Sciences, Incorporated Enzyme immunoassays and immunologic reagents
DE3900534A1 (de) 1989-01-10 1990-07-12 Boehringer Mannheim Gmbh Diagnostischer nachweis unter verwendung von chimaeren antikoerpern
JP2003501096A (ja) 1999-06-07 2003-01-14 ネオルクス コーポレイション ストレプトアビジン発現性遺伝子融合およびその使用方法
HN2004000285A (es) 2003-08-04 2006-04-27 Pfizer Prod Inc ANTICUERPOS DIRIGIDOS A c-MET
EP2385069A3 (en) 2003-11-12 2012-05-30 Biogen Idec MA Inc. Neonatal Fc rReceptor (FcRn)- binding polypeptide variants, dimeric Fc binding proteins and methods related thereto
JP2008520186A (ja) 2004-10-01 2008-06-19 マックス−プランク−ゲゼルシャフト・ツア・フェルデルング・デア・ヴィッセンシャフテン・エー・ファオ 哺乳類ｅａｇ１イオンチャネルタンパク質に対する新規の抗体
LT2620450T (lt) 2005-03-08 2019-02-11 Pfizer Products Inc. Anti-ctla-4 antikūnų kompozicijos
WO2006104989A2 (en) 2005-03-29 2006-10-05 Verenium Corporation Altered antibody fc regions and uses thereof
DK2390267T3 (da) * 2005-06-07 2013-08-26 Esbatech A Novartis Co Llc Stabile og opløselige antistoffer, der hæmmer TNF(alfa)
WO2009005813A1 (en) 2007-07-02 2009-01-08 Wyeth Modulators of axl for use in treating bone disorders
EP2217716A4 (en) * 2007-11-09 2011-02-09 Salk Inst For Biological Studi USE OF TAM RECEPTOR INHIBITORS AS ANTIMICROBIAL AGENTS
JP5909442B2 (ja) * 2009-05-11 2016-04-26 ユー３・ファーマ・ゲーエムベーハー ヒト化ａｘｌ抗体

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5468634A (en) * 1991-06-24 1995-11-21 The University Of North Carolina At Chapel Hill Axl oncogene
WO1997034636A1 (en) * 1996-03-20 1997-09-25 Immunomedics, Inc. Humanization of an anti-carcinoembryonic antigen anti-idiotype antibody and use as a tumor vaccine and for targeting applications
EP1382969A1 (en) * 2002-07-17 2004-01-21 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Diagnosis and prevention of cancer cell invasion
WO2009062690A1 (en) * 2007-11-12 2009-05-22 U3 Pharma Gmbh Axl antibodies

Also Published As

Publication number Publication date
WO2010130751A1 (en) 2010-11-18
JP2012526530A (ja) 2012-11-01
TW201105348A (en) 2011-02-16
MX2011011825A (es) 2011-12-06
RU2011150183A (ru) 2013-06-20
CN102421802A (zh) 2012-04-18
JP5909442B2 (ja) 2016-04-26
JP2016011306A (ja) 2016-01-21
US20120117670A1 (en) 2012-05-10
CN102421802B (zh) 2014-08-20
ZA201107529B (en) 2012-06-27
AR076564A1 (es) 2011-06-22
BRPI1013428A2 (pt) 2019-07-02
EP2430050A1 (en) 2012-03-21
US8841424B2 (en) 2014-09-23
CA2759836A1 (en) 2010-11-18
KR20120035145A (ko) 2012-04-13
RU2571224C2 (ru) 2015-12-20
US20150037323A1 (en) 2015-02-05
IL216147A (en) 2016-04-21
RU2015147287A (ru) 2017-05-12
AU2010247464A1 (en) 2011-11-10
IL216147A0 (en) 2012-01-31
TWI526223B (zh) 2016-03-21
TW201509431A (zh) 2015-03-16

Similar Documents

Publication Publication Date Title
US8841424B2 (en) Humanized AXL antibodies
AU2008323206B2 (en) AXL antibodies
JP2023099088A (ja) 活性化可能抗ｐｄｌ１抗体、およびその使用方法
JP6033293B2 (ja) 抗Ａｘｌ抗体及びその使用
RU2590711C2 (ru) Новое антитело против dr5
TW202016135A (zh) Ｐｓｍａ結合劑及其用途
US20140370037A1 (en) Dll3 modulators and methods of use
JP2014522639A (ja) 抗Ａｘｌ抗体及びその使用
KR20240052881A (ko) Pmel17에 대한 항체 및 이의 접합체
EP2270053A1 (en) Humanized AXL antibodies
IL274008B2 (en) Anti-msln antibody and pharmaceutical composition comprising same for cancer treatment
JP2025038001A (ja) Ｐｄｇｆ－ｂおよびｐｄｇｆ－ｄに結合する抗原結合分子ならびにその使用
US20150152193A1 (en) Axl antibodies
JP2025516434A (ja) 抗ｃｄ７３抗体およびその使用
HK1147275B (en) Axl antibodies
HK1189622B (en) Novel anti-dr5 antibody

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired